Why this site exists
For decades, GLP-1 medications meant needles. That changed in 2019 when Novo Nordisk launched Rybelsus, the first FDA-approved oral GLP-1 — though its approval was for type 2 diabetes, not weight loss. The real inflection point came in December 2025, when the FDA approved a 25 mg oral Wegovy pill for weight management. Four months later, in April 2026, Eli Lilly's Foundayo (orforglipron) became the second FDA-approved oral GLP-1 designed for weight loss.
Meanwhile, a parallel industry of compounded oral GLP-1s — sublingual drops, lozenges, dissolvable tablets — expanded rapidly on telehealth platforms, often with marketing that suggests equivalence to FDA-approved drugs. Some providers are solid; others have drawn FDA warning letters. Patients trying to sort through all of this find themselves reading ad copy when they want information.
Our goal is to be the site you can trust when you search "oral GLP-1" — with verified pricing, plain-language explanations of the clinical evidence, and honest provider reviews that acknowledge the good and the bad.
How we review providers
Every telehealth provider mentioned on this site goes through a structured evaluation:
- Regulatory standing. Any FDA warning letter, class-action involvement, or significant regulatory action is disclosed in the review, dated, and linked to primary sources.
- Pharmacy partnerships. We verify accreditations where publicly disclosed (LegitScript, URAC, ACHC, PCAB) and name pharmacy partners when companies publish them.
- Pricing transparency. All prices are verified directly from provider websites at the time of publication, with a "last verified" date on each review. Compounded-product prices and FDA-approved drug prices are clearly separated.
- Format honesty. If a provider sells "oral tirzepatide drops," we note that there are no published human efficacy data for such formulations. We don't pretend compounded products are equivalent to FDA-approved ones.
- Clinical context. Reviews reference peer-reviewed evidence (OASIS, STEP, SURMOUNT, ATTAIN, PIONEER trials) to contextualize efficacy claims.
How we make money
oralglp-1s.com is an affiliate-supported editorial site. When you click a provider link and sign up, we may earn a commission. That revenue is what makes independent content like this financially viable.
Here's what doesn't change based on whether we get paid:
- Editorial ratings — we rate providers on evidence and transparency, not commission rates
- FDA warning letter disclosures — published regardless of commercial relationship
- Factual accuracy — numbers and dates are verified to primary sources, full stop
Every commissionable link is labeled "Paid link" per current FTC guidance. If you prefer not to use affiliate links, our provider reviews are readable without clicking them, and you can search directly for any provider we discuss.
A note on compounded medications. We cover both FDA-approved oral GLP-1s (Wegovy pill, Foundayo, Rybelsus) and compounded oral products from licensed telehealth pharmacies. Compounded drugs are not FDA-approved. We flag this clearly in every relevant article. We are not pro-compounded or anti-compounded; we aim to present accurate information and let you make an informed decision with your clinician.
Our editorial standards
Primary sources first
Claims on this site are traceable to primary sources: FDA announcements, published clinical trials (NEJM, Lancet, JAMA, Diabetes Care, Clinical Pharmacokinetics), manufacturer prescribing information, and company press releases. We link to these sources directly whenever possible.
Zero fabrication policy
We do not invent statistics, testimonials, reviews, or "patient stories." If a number appears on this site, it came from a verified source. If a quote appears, it was actually said or written. This is a non-negotiable standard.
Regular updates
The oral GLP-1 landscape is changing quickly. Articles include a "last updated" date and are reviewed for accuracy on a rolling basis. Pricing is re-verified quarterly. Regulatory changes (FDA approvals, warning letters, enforcement actions) trigger immediate updates.
Clear disclaimers
Every article that discusses a medication includes the appropriate safety and regulatory context. Compounded-product disclaimers appear on every article where compounded drugs are discussed.
What this site is not
- Not medical advice. Nothing on this site is a substitute for a conversation with a licensed healthcare provider who knows your medical history.
- Not a pharmacy. We don't prescribe, dispense, ship, or sell medications. Every provider we link to is an independent third party.
- Not affiliated with drug manufacturers. We're not sponsored by Novo Nordisk, Eli Lilly, or any telehealth platform.
Contact us
Questions, corrections, or feedback? We read every message. Email us at hello@oralglp-1s.com or visit the contact page.
Corrections: if you spot a factual error anywhere on the site, please email corrections@oralglp-1s.com. We take accuracy seriously and will update the article with a visible correction note.